ASRT
Assertio Holdings Inc

15,814
Mkt Cap
$63.78M
Volume
130,274.00
52W High
$15.15
52W Low
$7.71
PE Ratio
-2.11
ASRT Fundamentals
Price
$9.94
Prev Close
$9.90
Open
$9.50
50D MA
$11.48
Beta
1.31
Avg. Volume
50,611.86
EPS (Annual)
-$3.40
P/B
0.60
Rev/Employee
$2.15M
Loading...
Loading...
News
all
press releases
Assertio (NASDAQ:ASRT) Sees Strong Trading Volume - Should You Buy?
Assertio (NASDAQ:ASRT) Sees Large Volume Increase - What's Next...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split
Assertio Holdings, Inc. (Assertio or the Company) (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (the Certificate of Amendment) on...
Business Wire·6d ago
News Placeholder
Assertio (NASDAQ:ASRT) Rating Increased to Buy at Wall Street Zen
Wall Street Zen raised Assertio to a "buy" rating in a research note on Saturday...
MarketBeat·1mo ago
News Placeholder
Assertio (NASDAQ:ASRT) Issues Quarterly Earnings Results, Beats Expectations By $0.19 EPS
Assertio (NASDAQ:ASRT - Get Free Report) issued its quarterly earnings results on Monday. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of...
MarketBeat·2mo ago
News Placeholder
Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates
Assertio (ASRT) delivered earnings and revenue surprises of +237.50% and +83.86%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Assertio Reports Third Quarter 2025 Financial Results
Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients...
Business Wire·2mo ago
News Placeholder
Earnings Outlook For Assertio Holdings
read more...
Benzinga·2mo ago
News Placeholder
Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -100.00% and +0.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
New Strong Sell Stocks for September 23rd
ATS, ASRT and DBVT have been added to the Zacks Rank #5 (Strong Sell) List on September 23, 2025.
Zacks·3mo ago
News Placeholder
New Strong Sell Stocks for September 19th
ASRT, CE and ARR have been added to the Zacks Rank #5 (Strong Sell) List on September 19, 2025.
Zacks·3mo ago
<
1
2
...
>

Latest ASRT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.